BIOX(BIOX)
BIOX
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2027E | FY2028E | FY2029E |
|---|---|---|---|
| Revenue Avg | $379M | $511M | $579M |
| Low | $379M | $511M | $579M |
| High | $379M | $511M | $579M |
| EBITDA Avg | $47M | $63M | $72M |
| Low | $47M | $63M | $72M |
| High | $47M | $63M | $72M |
| EBIT Avg | $31M | $41M | $47M |
| Low | $31M | $41M | $47M |
| High | $31M | $41M | $47M |
| Net Income Avg | $3M | $35M | $52M |
| Low | $3M | $35M | $52M |
| High | $3M | $35M | $52M |
| EPS Avg | $0.05 | $0.56 | $0.82 |
| Low | $0.05 | $0.56 | $0.82 |
| High | $0.05 | $0.56 | $0.82 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 | 1 / 1 |